▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Happiness Biotech Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.85.
The current consensus among 0 investment analysts is to n/a stock in Happiness Biotech Group. This rating has held steady since December 2020, when it changed from a Buy consensus rating.
Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powder, cordyceps mycelia, ejiao solution, American ginseng, and other products. It also offers a range of ganoderma lucidum products, such as essence oil, cleansing milk, shampoo, shower gel, and nourishing cream products under the Cai Zhi Ning brand, as well as edible fungi. In addition, the company provides disinfectants, non-medical face masks, and COVID-19 anti-body testing kits. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.